Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
- Posted
- August 10, 2023
- Closed
- November 20, 2024
- Cost sharing
- No
- Instrument
- Grant
- Assistance listing
- 93.395
- Archives
- December 20, 2024
Program funding history
Awards made under Assistance Listing 93.395 across FY2025–FY2027, from public federal spending records.
- FY2025 obligated
- $1.3B
- FY2026 obligated
- $1.3B
- FY2027 (to date) obligated
- $0
- Awards in window
- 3,624
Top recipients: The Univeristy of Texas M.d. Anderson Cancer Center, Dana-farber Cancer Institute, Inc., Icahn School of Medicine at Mount Sinai, Fred Hutchinson Cancer Center, Sloan-kettering Institute for Cancer Research
Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →
Synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for identification of small molecules that function to elucidate the biology of disease as chemical probes or function as agonists or antagonists of disease target(s) for therapy or immunotherapy. The NOFO is intended to support discovery research for the identification of validated hits relevant to health-related outcomes of participating NIH Institutes. Stages of discovery research covered by this NOFO include: 1) assay development for specific biological targets and disease mechanisms relevant to the mission of participating NIH Institutes with the intent to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets, or as pre-therapeutic leads; 2) screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches to identify initial screening hits; 3) hit validation, including implementation of secondary assays that are orthogonal to the primary assay, advanced cheminformatics analysis and initial medicinal chemistry inspection to prioritize the hit set, and follow-up assays to characterize mode and mechanism of action of the validated hits; 4) hit-to-lead optimization, including SAR to optimize target engagement, selectivity and to minimize chemical liabilities, ADME, PK and PD studies, and, if appropriate, in vivo modeling to test efficacy or biological effects.
Who can apply
- Public and State controlled institutions of higher education
- Special district governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- County governments
- Public housing authorities/Indian housing authorities
- For profit organizations other than small businesses
- Small businesses
- Native American tribal governments (Federally recognized)
- City or township governments
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- State governments
- Private institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Independent school districts
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
The official record
Grants.gov published the official terms and dates of this opportunity; this page keeps them as they were listed.
View on Grants.gov Full announcement
New to federal funding? How to read an announcement · Who can apply · How grants work
Tell me when this program posts again
This round has closed. One email the morning after this program is posted again under a new number (we watch for about two years), and one more about a week before that round closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.
Similar grants
- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
- HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
- Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
- Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
- Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Same-day alerts, matched to you
The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.
Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.
See pricing